Literature DB >> 11282208

Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).

M Conacher1, J Alexander, J M Brewer.   

Abstract

The ability of non-ionic surfactant vesicles to induce systemic immune responses in mice following oral immunisation was studied using a standard antigen (bovine serum albumin), a synthetic measles peptide and an influenza sub-unit vaccine. The effectiveness of this formulation was significantly increased by incorporating bile salts (in particular deoxycholate) into the formulation. We have named the resulting vesicles bilosomes. We found that the most effective immunisation protocol was to give two doses of vaccine three days apart and then repeat this protocol two weeks later. Following this method, preparation of measles peptide in bilosomes produced a specific cell mediated response, as measured by splenocyte proliferation and IL-2 production. Of particular significance, these studies demonstrate that oral administration of bilosomes incorporating the influenza sub-unit vaccine could induce as potent an antibody response as the parenterally administered vaccine containing the same quantity of antigen. In addition, the Th1/Th2 balance, as measured by antibody subclasses, was similar whether animals were immunised by the oral or the parenteral vaccine route. As bilosomes are prepared from naturally occurring lipids and have no apparent toxicity associated with their use, they represent a useful modification of conventional lipid vesicle based systems for the oral delivery of proteins and peptides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282208     DOI: 10.1016/s0264-410x(00)00537-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

2.  Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer's patch targeting using a polyplex-loaded liposomes.

Authors:  Sunee Channarong; Wanpen Chaicumpa; Nuttanan Sinchaipanid; Ampol Mitrevej
Journal:  AAPS PharmSciTech       Date:  2010-12-31       Impact factor: 3.246

Review 3.  Bile acid transporter-mediated oral drug delivery.

Authors:  Feiyang Deng; You Han Bae
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

4.  Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes.

Authors:  Anshuman Shukla; Bhupinder Singh; O P Katare
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines.

Authors:  Jitinder S Wilkhu; Sarah E McNeil; David E Anderson; Yvonne Perrie
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

6.  Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.

Authors:  Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

Review 7.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

8.  Novel approaches to oral immunization for hepatitis B.

Authors:  Shailja Tiwari; Suresh P Vyas
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 9.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

10.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.